Testing and Linkage to Care for Injecting Drug Users in Kenya
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
Testing and Linkage to Care for Injecting Drug Users in Kenya:
Interventions for people who inject drugs (PWID) in sub-Saharan African have been almost
entirely absent, despite the fact that in countries like Kenya they contribute a growing
proportion of incident HIV infections. This study will leverage a historic decision in Kenya
to launch needle exchange program (NSP) and related services for this most-at-risk population
(MARP). The investigators will use this NSP/MARP platform to seek out PWID, deliver rapid HIV
testing, point of care CD4 count and link to ART using peer case managers, and evaluate
community viral load impact using a stepped wedge cluster-randomized design. Lessons learned
will have important applicability throughout sub-Saharan African.
HCV Among PWID in Kenya: A Supplement to the TLC-IDU study:
The prevalence of HCV in Kenya, where an increasing number of people who inject drugs (PWID)
live and are becoming HIV- as well as HCV-infected, has not been defined. We will establish
HCV prevalence among PWID in Nairobi, Western, and Coastal region by adding HCV rapid and
confirmatory tests in our parent PWID study (TLC-IDU Kenya); deliver appropriate counseling
and treatment options to those eligible; collect HCV treatment adherence data; and
disseminate study findings. These data will provide novel and relevant information about HCV
and HIV co-infection in Kenya among PWID that will be immediately applicable in terms of
public health impact to national and regional HCV testing, counseling, and clinical
management policy.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborators:
Kenya National AIDS & STI Control Programme National Institute on Drug Abuse (NIDA) NYU Langone Health